Inhibition of the Renin-Angiotensin-Aldosterone System for Cerebrorenal Protection

被引：2
作者：
Heerspink, H. J. Lambers [1 ]
机构：
[1] Univ Groningen, Univ Med Ctr Groningen, Dept Clin Pharmacol, NL-9713 AV Groningen, Netherlands
来源：
BRAIN, STROKE AND KIDNEY | 2013年 / 179卷
关键词：
DIETARY-SODIUM RESTRICTION; CHRONIC KIDNEY-DISEASE; BLOOD-PRESSURE; CARDIOVASCULAR OUTCOMES; HYPERTENSIVE PATIENTS; ALISKIREN TRIAL; ACE-INHIBITION; STROKE; MORTALITY; TELMISARTAN;
D O I：
10.1159/000346717
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Blood pressure is a strong risk factor for ischemic and atherosclerotic events such as stroke. Blood pressure is often elevated in patients with chronic kidney disease. Consequently, chronic kidney disease patients are at high risk of developing cardiovascular and cerebrovascular damage. Blood pressure reduction by means of inhibiting the renin-angiotensin-aldosterone system (RAAS) reduces the risk of stroke. There is evidence available in the primary and secondary prevention of stroke that RAAS blockade exerts cerebrovascular protective effects independent of blood pressure lowering. This chapter discusses the role of RAAS blockade for the prevention and treatment of stroke in chronic kidney disease. The role of dual RAAS blockade will be reviewed and alternative strategies to enhance the effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers will be provided. Copyright (C) 2013 S. Karger AG, Basel
引用
收藏
页码：7 / 14
页数：8
相关论文
共 34 条
  • [21] Proinflammatory actions of angiotensins
    Ruiz-Ortega, M
    Lorenzo, O
    Suzuki, Y
    Rupérez, M
    Egido, J
    [J]. CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 2001, 10 (03) : 321 - 329
  • [22] RETRACTED: Effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high cardiovascular risks: KYOTO HEART Study (Retracted Article)
    Sawada, Takahisa
    Yamada, Hiroyuki
    Dahlof, Bjorn
    Matsubara, Hiroaki
    [J]. EUROPEAN HEART JOURNAL, 2009, 30 (20) : 2461 - 2469
  • [23] Morbidity and mortality after stroke, eprosartan compared with nitrendipine for secondary prevention -: Principal results of a prospective randomized controlled study (MOSES)
    Schrader, J
    Lüders, S
    Kulschewski, A
    Hammersen, F
    Plate, K
    Berger, J
    Zidek, W
    Dominiak, P
    Diener, HC
    [J]. STROKE, 2005, 36 (06) : 1218 - 1224
  • [24] Moderate dietary sodium restriction added to angiotensin converting enzyme inhibition compared with dual blockade in lowering proteinuria and blood pressure: randomised controlled trial
    Slagman, Maartje C. J.
    Waanders, Femke
    Hemmelder, Marc H.
    Woittiez, Arend-Jan
    Janssen, Wilbert M. T.
    Lambers Heerspink, Hiddo J.
    Navis, Gerjan
    Laverman, Gozewijn D.
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2011, 343
  • [25] Angiotensin II, the immune system and renal diseases: another road for RAS?
    Suzuki, Y
    Ruiz-Ortega, M
    Gomez-Guerrero, C
    Tomino, Y
    Egido, J
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2003, 18 (08) : 1423 - 1426
  • [26] HIGH SODIUM-CHLORIDE DIETS INJURE ARTERIES AND RAISE MORTALITY WITHOUT CHANGING BLOOD-PRESSURE
    TOBIAN, L
    HANLON, S
    [J]. HYPERTENSION, 1990, 15 (06) : 900 - 903
  • [27] Turnbull F, 2003, LANCET, V362, P1527
  • [28] UNGER T, 1988, CIRCULATION, V77, P40
  • [29] Effects of dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losartan
    Vogt, Liffert
    Waanders, Fernke
    Boornsma, Frans
    de Zeeuw, Dick
    Navis, Gerjan
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2008, 19 (05): : 999 - 1007
  • [30] Ischemic injury in experimental stroke depends on angiotensin II
    Walther, T
    Olah, L
    Harms, C
    Maul, B
    Bader, M
    Hörtnagl, H
    Schultheiss, HP
    Mies, G
    [J]. FASEB JOURNAL, 2002, 16 (02) : 169 - 176
1234